According to the World Health Organization, studies have reported that 10-20% of COVID-19 patients will go on to develop long COVID*.
Research is still on the way to identify long COVID and gathering deeper understanding of the natural history of this disease, alongside its management and longer-term sequelae. However, these efforts will not be complete without capturing patients’ experience and the disease impact on their quality of life which can be measured through Patient-Reported Outcomes (PROs).
This webinar aims to further understand long COVID assessments regarding PRO instruments and the concepts that have been researched.
The speakers will share their findings on Patient-Reported Outcomes (PROs) from ePROVIDETM databases, ClinicalTrials.gov, and Medline, to identify PRO instruments developed for and used in long COVID. Among 156 PRO instruments developed for COVID-19, identified in the PROQOLIDTM database, only a small number were specific for long COVID (8 PROs). This was also observed in published and on-going long COVID studies. As so few PROs are developed specifically for use in long COVID patients, many generic instruments and other disease-specific instruments were used in the clinical trials such as the EuroQoL 5-Dimension (EQ-5D), the SF-36 Health Survey (SF-36), the Hospital Anxiety and Depression Scale (HADS) or the Modified Medical Research Council Dyspnea Scale (mMRC).
The use of PROs is essential in assessing the impact of long COVID on patient’s quality of life and to facilitate the research and development of treatments. This webinar aims to discuss the potential need of further research to develop disease-specific PROs for the assessment of long COVID. Mapi Research Trust COA experts can help identify the gaps or assist in the selection of fit-for-purpose PRO instruments in any therapeutic indications. The ePROVIDETM platform and COA databases are valuable resources for researchers who are preparing clinical trials in long COVID.
*World Health Organization. “Post COVID-19 condition (Long COVID).” WHO, 7 Dec. 2022.
What you will learn
- Discover an up-to-date information source about use of PROs in long COVID
- Become familiar with the concepts of interest from the patients’ perspective in the management of long term effects of COVID-19 and its PRO landscape
- Understand how ePROVIDETM COA databases can help screening and selecting appropriate PROs for the use in any therapeutic indications
Who should attend
This webinar is of interest to:
- Clinical scientists, epidemiologists and those involved in clinical trials and comparative effectiveness research
- COA scientist and psychometricians involved in development and validation of instruments for PROs related to COVID-19.
Nadine Kraft, M.Sc.
Team Lead, Database Unit, Mapi Research Trust
Nadine Kraft is the Team Lead of Mapi Research Trust’s Database Unit. Prior to her work at Mapi Research Trust she was complementing her studies working in an international medical technology company. At the University of Salzburg, she graduated with a M.Sc. in Psychology and a specialization in cog. Neuroscience and psychological diagnostic, including psychometric properties.
Sara Carvalho, Ph.D.
Lead Outcomes Researcher, Mapi Research Trust
Sara Carvalho is the manager of the team of experts in consultancy in COA strategies at Mapi Research Trust.
She has worked in a wide range of therapeutic areas, including oncology, cardiology, infectious and inflammatory diseases. She has authored manuscripts published in scientific peer-reviewed journals as well as presentations for international scientific conferences.
Sara holds a Ph.D. in Cancer Research from The Institute of Cancer Research, a Master in Cellular and Molecular Biology and a master’s in clinical Trials and Medical Affairs.